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Background: Patients with HIV-associated tuberculosis (TB) often have their TB and HIV managed in separate
vertical programs that offer care for each disease with little coordination. Such “siloed” approaches are associated
with diagnostic and treatment delays, which contribute to unnecessary morbidity and mortality. To improve TB/HIV
care coordination and early ART initiation, we integrated HIV care and treatment into two busy TB clinics in Zambia.
We report here the effects of our intervention on outcomes of linkage to HIV care, early ART uptake, and TB
treatment success for patients with HIV-associated TB in Lusaka, Zambia.
Methods: We provided integrated HIV treatment and care using a “one-stop shop” model intervention. All new or
relapse HIV-positive TB patients were offered immediate HIV program enrolment and ART within 8 weeks of anti-TB
therapy (ATT) initiation. We used a quasi-experimental design, review of routine program data, and survival analysis
and logistic regression methods to estimate study outcomes before (June 1, 2010—January 31, 2011) and after
(August 1, 2011—March 31, 2012) our intervention among 473 patients with HIV-associated TB categorized into
pre- (n = 248) and post-intervention (n = 225) cohorts.
Results: Patients in the pre- and post-intervention cohorts were mostly male (60.1% and 52.9%, respectively) and
young (median age: 33 years). In time-to-event analyses, a significantly higher proportion of patients in the post-
intervention cohort linked to HIV care by 4 weeks post-ATT initiation (53.9% vs. 43.4%, p = 0.03), with median time
to care linkage being 59 and 25 days in the pre- and post-intervention cohorts, respectively. In Cox proportional
hazard modelling, patients receiving the integration intervention started ART by 8 weeks post-ATT at 1.33 times the
rate (HR = 1.33, 95% CI: 1.00–1.77) as patients pre-intervention. In logistic regression modelling, patients receiving
the intervention were 2.02 times (95% CI: 1.11–3.67) as likely to have a successful TB treatment outcome as patients
not receiving the intervention.
Conclusions: Integrating HIV treatment and care services into routine TB clinics using a one-stop shop model
increased linkage to HIV care, rates of early ART initiation, and TB treatment success among patients with HIV-
associated TB in Lusaka, Zambia.
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Dual tuberculosis (TB) and HIV epidemics have dispropor-
tionately affected sub-Saharan Africa (SSA). In 2016, an
estimated 30% of all incident TB in the World Health
Organization (WHO) African region, or approximately
764,000 total TB cases, were HIV-associated [1]. In
Zambia, one of the 30 WHO high TB burden countries,
58% of patients with new or relapse tuberculosis have HIV
infection [1]. In Zambia and throughout SSA, patients with
HIV-associated TB often have their TB and HIV managed
independently, typically in disease-specific vertical care
programs [2, 3].
Historically, these vertical programs have provided care
for each disease with little to no coordination, relying in-
stead upon separate clinics and different health workers
[4]. As a result, these “siloed” programs are associated
with diagnostic and treatment delays for both diseases,
poor HIV counselling and testing (HCT) uptake, delays in,
and low rates of, linkage to HIV care and antiretroviral
therapy (ART) initiation, and increased patient morbidity
and mortality [5–8] These non-integrated approaches
have also been hampered by several operational chal-
lenges, including: a lack of resource sharing between TB
and HIV programs; uncoordinated visit scheduling, which
increases patient costs and work absenteeism; and poor
communication between TB and HIV clinics about pre-
scribed drug regimens, treatment-related side effects, and
drug-drug interactions for shared patients [3, 9–11]. Im-
portantly, the vertical approach also threatens TB infec-
tion control efforts when co-infected patients with newly
diagnosed or undiagnosed TB congregate with other
HIV-positive patients in ART clinics [12].
In response to these challenges, several models of coordi-
nated TB/HIV care have emerged, reflecting a spectrum of
service integration. These models range from referral-based
approaches in which co-infected patients are directed from
the TB clinic to a separate ART clinic, and vice versa, for
TB/HIV services to a more integrated “one-stop shop”
model where one healthcare team provides fully integrated
TB/HIV services under one roof [3, 11]. Integrated TB/HIV
care, in which the same healthcare team provides services
to patients with HIV-associated TB, offers potential advan-
tages over standard approaches. First, it allows clinicians to
better co-manage TB/HIV co-infection and attendant com-
plications, such as drug-drug interactions, side effects, and
toxicities. Second, integrated care helps counsellors and
treatment supporters provide psychosocial support and ad-
herence counselling to co-infected patients in the same lo-
cation. Finally, integrated TB/HIV services helps patients
better access treatment and care, including ART, in a timely
fashion, without having to wait in multiple clinics within
one or more health facilities [3].
For ART provision, clinical trial evidence clearly demon-
strates the importance of starting ART early, within 8 to12 weeks, to reduce HIV-associated TB mortality, particu-
larly for patients with advanced immunosuppression [13–
16]. Despite the known benefits, however, several barriers
to early ART initiation in patients with HIV-associated TB
have hampered uptake of this evidence-based intervention
in routine care settings. These barriers include poor coord-
ination between vertical TB and HIV programs, patient and
provider reluctance, delays in laboratory testing and result
reporting, and the excessive number of steps patients must
navigate along the HIV and TB care cascades [5, 9, 17, 18].
In Zambia, while recent progress has been made in
improving the proportion of HIV-positive TB patients
on ART reported to WHO, from 60% in 2012 to 83% in
2016 [1, 19], challenges remain. For example, in 2016,
ART coverage as a percentage of the estimated number
of new HIV-associated TB cases nationally stood at just
under 60%, suggesting a need for continued work to im-
prove access to ART for HIV-positive TB patients [1].
For HIV-positive TB patients accessing ART, little is
known about the average time to ART initiation in rou-
tine care settings in SSA. Furthermore, there is limited
data from Zambia and the region evaluating integrated
TB/HIV care models in real-world clinical settings, and,
in particular, few reports examining models that provide
comprehensive HIV services, including ART initiation
and follow-up, within TB clinics.
To increase the proportion of patients with
HIV-associated TB who link to HIV care and initiate ART
early in routine TB clinical settings, we piloted integration
of HIV care and treatment—including HIV care enrolment
and ART initiation and follow-up—into two busy TB
clinics in Lusaka using a one-stop shop model. The Centre
for Infectious Disease Research in Zambia (CIDRZ) imple-
mented the pilot in partnership with the Lusaka District
Health Office (DHO) of the Zambian Ministry of Health
(MOH). We aim here to assess the feasibility of our pilot
intervention and to evaluate its effects on timely linkage
to HIV care, early ART uptake, and TB treatment out-
comes among HIV-associated TB patients in Lusaka,
Zambia.
Methods
Study design, population, and setting
We conducted a quasi-experimental before-after study
from June 1, 2010 through March 31, 2012 to assess
whether our TB/HIV treatment and care integration
intervention had an effect on two primary outcomes:
linkage to HIV care and early ART initiation. We defined
“linkage to HIV care” as documented evidence of having
enrolled in the national HIV program. We defined
“early” ART initiation as a patient receiving ART within
8 to 12 weeks of anti-TB therapy (ATT) start. Patients
were eligible for study inclusion if they had a recorded
ATT start date documented in the TB register, and had
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were already on ART at the time of TB diagnosis; trans-
ferred into a study site TB clinic from a non-study site;
were receiving HIV care through a private clinic or
non-governmental organization; started ATT outside the
defined pre- and post-intervention time periods; or were
concurrently enrolled in another study. No patients with
documented multi-drug resistant TB received treatment
at primary health centre level during the study period.
We observed outcomes of interest among patients meet-
ing study eligibility criteria at two TB clinics situated within
two CIDRZ-supported primary health centres in Lusaka,
Zambia—“Clinic A” and “Clinic B”. Observations occurred
during an 8-month pre-intervention period (June 1, 2010
through January 31, 2011) and an 8-month
post-intervention period (August 1, 2011 to March 31,
2012). Patients who started ATT during the
pre-intervention period were considered part of a “pre-in-
tervention cohort”; those who initiated ATT during the
post-intervention period were part of the “post-interven-
tion cohort”. The pre- and post-intervention periods were
exactly the same duration, and were specified to enable an
intervening 1-month “wash-out” window between when
the last patient joining the pre-intervention cohort com-
pleted their 6-month ATTcourse and the start of our inter-
vention during the post-intervention period.
Standard of care
Patients in the pre-intervention cohort received the
standard of care. Under the standard of care, patients
with TB/HIV co-infection are provided TB and HIV care
separately in two distinct clinics using a referral-driven
model. Typically, the standard of care follows one of two
clinical pathways (detailed below) depending on whether
HIV or TB is diagnosed first: 1) a newly diagnosed or
established HIV-positive patient undergoes evaluation
and treatment for TB; or 2) a new TB patient tests posi-
tive for HIV.
Newly diagnosed HIV-positive patients may be referred
to the ART clinic from any of a number of locations in the
facility, including the HCT room, the maternal & child
health department, the out-patient department, or other
department. At the ART clinic, the patient is enrolled in
the national HIV program (requiring registration in the
SmartCare electronic medical record system), and under-
goes baseline clinical and laboratory evaluation in prepar-
ation for ART initiation. Those newly establishing HIV
care also receive co-trimoxazole preventive therapy (CPT).
All newly diagnosed HIV-positive patients undergo TB
screening at the time of their first clinical evaluation by
sputum smear microscopy, or, less commonly, by Xpert
MTB/RIF (Cepheid, Sunnyvale, CA, USA) where available.
Chest x-ray is not routinely available in all health facilities,
and where available often requires that a user fee be paid.Patients found to be smear-negative are assessed by
a clinician and may be treated empirically based on
clinical findings suggestive of TB disease. After es-
tablishing HIV care, HIV-positive patients are
screened for TB-compatible symptoms at every ART
clinic visit per national guidelines [20, 21].
HIV-positive patients diagnosed with TB clinically
(i.e. based on symptoms, physical exam, and/or chest
x-ray) or microbiologically (i.e. by smear microscopy
or Xpert MTB/RIF) are referred to the TB clinic to
initiate ATT.
All newly diagnosed TB patients are offered HCT at
enrolment into TB care, typically within the TB Clinic it-
self. To that end, the TB clinic usually houses one or
more HCT counselling rooms, and is staffed by one to
two nurses and peer health educators. Patients testing
HIV-positive are referred to the ART Clinic to establish
HIV care and undergo further evaluation for ART initi-
ation as detailed above.
All patients with drug-susceptible TB, irrespective of HIV
status, receive first-line ATT with a WHO-recommended,
6-month rifampicin-based fixed-dose combination regi-
men. ATT is initiated in the TB clinic according to national
guidelines from the National Tuberculosis & Leprosy
Control Programme (NTP). In Zambia, TB treatment is
supported by a lay cadre of peer health educators who
provide psychosocial support and adherence counselling to
patients.
HIV care and treatment integration intervention
We implemented the same model of TB/HIV service in-
tegration in two routine TB clinics—Clinic A and Clinic
B. The integration intervention was introduced first at
Clinic A in August 2011, and then at Clinic B in October
2011. The intervention had five core components: 1)
health worker training and mentorship; 2) timely
provider-initiated HIV testing and counselling (PITC); 3)
on-site HIV care enrolment; 4) dedicated ART clinic
days; and 5) synchronized TB and HIV patient
follow-up. We further describe these components below.
We trained all nurses and clinical officers from both the
TB clinic and ART clinic on TB/HIV co-management.
Training emphasized proper ATT and ART prescribing
practices, and recognition and management of drug-
related side effects and toxicity. Importantly, clinicians
were trained to begin ART for all co-infected patients as
soon as possible, and preferably within 8 to 12 weeks of
ATT initiation, regardless of CD4 count. CIDRZ clinician
mentors worked intensively with facility staff for approxi-
mately 6 months at the start of the intervention to
reinforce training concepts. CIDRZ peer educators were
trained to provide health education talks to patients on
the relationship between TB and HIV and the need for
early and sustained co-treatment.
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enrolment into TB care (Fig. 1). TB patients newly iden-
tified as HIV-positive who had not previously enrolled in
HIV care were informed about the importance of linking
to HIV care and starting ART, and were offered immedi-
ate enrolment into HIV care on site. MOH nursing staff
conducted initial HIV care enrolment procedures in line
with national guidelines in place at the time of the study,
including: completion of the MOH HIV care enrolment
form and blood draws for baseline laboratory tests (in-
cluding complete blood count, CD4, creatinine, and liver
function tests). Following HIV care enrolment, patients
were scheduled for an on-site ART initiation visit with a
clinical officer to undergo a thorough clinical evaluation,
including history, physical exam, and laboratory test re-
sult review, and to start ART. HIV-positive TB patients
already on ART at the time of ATT initiation were given
the option to continue their HIV care at the ART clinic
or to transfer their HIV care to the TB clinic for the
duration of ATT.Fig. 1 Integrated TB/HIV care patient flow. HIV, human immunodeficiency
ATT, anti-tuberculosis therapy; CPT, co-trimoxazole therapy; ART, anti-retrov
Leprosy ProgrammeTo ensure adequate patient follow-up and efficient use
of limited human resources for clinician staffing, each TB
clinic scheduled a weekly ‘ART clinic day’ when the same
MOH clinical officer was posted to provide “one-stop
shop” TB/HIV services, including ART initiation. On the
scheduled day, the MOH clinical officer evaluated
patients, conducted a physical exam, and reviewed lab
results and ART eligibility. Once patients enrolled in HIV
care, and initiated ART, they attended the TB clinic
according to their directly observed therapy (DOT) sched-
ule (daily, weekly or monthly) for TB treatment. ART and
TB follow-up was synchronized to harmonize clinical care
and drug collection, and to maximize patient convenience.
Specifically, the same clinical officer provided follow-up
clinical evaluation for both TB and HIV and attendant
co-morbidities and drug-related toxicities, and patients
collected both their antiretrovirals (ARVs) and TB medica-
tions from the same open-air drug dispensary at the TB
clinic. Eligible patients who declined to initiate ART
continued to receive TB care in the TB clinic and werevirus; TB, tuberculosis; PITC, provider-initiated testing and counselling;
iral therapy; ARVs, antiretrovirals; NTP, National Tuberculosis and
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tion, patients were referred to the ART clinic in each
facility for continuing their HIV care.
Data collection
For both the pre- and post-intervention periods, data were
collected prospectively during routine clinical care, and
recorded onto the following primary data sources: national
TB registers, patient TB treatment cards, paper-based HIV
care files, and the national SmartCare HIV electronic
medical record system. From these data sources, we subse-
quently abstracted patient data fields of interest, including:
age, sex, TB clinic serial number, TB registration date, TB
case identification number, TB registration type (i.e. new,
relapse, transferred in, treatment after default, or failure),
TB anatomical site (i.e. pulmonary TB [PTB] or
extra-pulmonary TB [EPTB]), TB treatment start date, re-
corded HIV status, SmartCare registration number, date of
HIV care enrolment, date of initial history and physical
exam, date of first CPT dispensation, date of first ART
dispensation, and WHO TB treatment outcome [22, 23].
Blank data fields were coded as “missing.” Per routine
medical record keeping practice, any patient without a
documented HIV care enrolment date is considered not to
have linked to care, and any patient without a first ART
dispensation date is thought not to have started ART. All
data were de-identified at the time of abstraction to protect
patient confidentiality. For the pre-intervention cohort, we
administratively censored HIV care enrolment and ART
initiation 6 months after the end of the pre-intervention
period, on July 31, 2011. Similarly, for the post-intervention
cohort, we censored HIV care enrolment and ART initi-
ation 6 months after the end of the post-intervention
period, on September 30, 2012.
Data analysis
Patient characteristics at the time of ATT initiation (i.e. at
“baseline”) were compared between pre- and post-
intervention cohorts using the Chi-square test for categor-
ical variables and the Student’s t-test for continuous vari-
ables. Simple proportions were used to describe the
primary outcomes: 1) the percentage of HIV-associated
TB patients newly enrolled in HIV care by 4, 8, and
12 weeks of ATT initiation; and 2) the percentage of
HIV-associated TB patients who newly initiated ART by
4, 8, and 12 weeks of starting ATT. We compared the pro-
portion of patients with a primary outcome between the
pre- and post-intervention cohorts, stratified by study
clinic, using the Cochran-Mantel-Haenszel test. We esti-
mated time to HIV care enrolment and ART initiation
using Kaplan-Meier methods with follow-up time mea-
sured from ATT initiation. Cumulative failure functions
were compared using the Log rank test. Cox proportional
hazard modelling was employed to estimate theassociation between exposure to our TB/HIV integration
intervention and ART start by 8 weeks post-ATT initi-
ation. We selected 8 weeks post-ATT initiation as our
threshold of interest as this is the WHO-recommended
time frame by which ART should be initiated in patients
with HIV-associated TB [24]. To estimate the effect of the
intervention on successful TB treatment (i.e. TB cure or
treatment completion), multi-variable logistic regression
modelling was used to determine the odds ratio and
associated 95% confidence interval (CI). For both our Cox
proportional hazard and logistic regression models, we ad-
justed for potential confounders that were selected on the
basis of clinical and programmatic plausibility, including
age, sex, intervention clinic, TB anatomical site, and TB
registration type (i.e. new case or cases of relapse, default,
or treatment after failure). Patients who transferred out or
had missing outcomes data were excluded from the
models. We considered two-sided p-values ≤0.05 statisti-
cally significant. All statistical analyses were performed
using STATA version 12.1 (College Station, TX, USA).
Ethics statement
Ethical approval for this study was granted by the Univer-
sity of Zambia Biomedical Research Ethics Committee and
the Institutional Review Board at the University of North
Carolina at Chapel Hill, without requiring patient consent
given the use of de-identified, routinely collected data.Results
Overview
Over the 22-month study period, Clinic A and B regis-
tered 578 and 983 total HIV-positive and HIV-negative
TB patients, respectively; HIV prevalence among TB
patients at Clinic A and B was 68.3% and 55.5%, respect-
ively. A total of 473 patients met study eligibility criteria,
including 248 patients in the pre-intervention cohort
and 225 patients in the post-intervention cohort.
Baseline patient characteristics
Patient age and sex distribution did not differ significantly
between the pre- and post-intervention cohorts, with a
majority of patients being male with a mean age of 33 years
(Table 1). Eighty-five percent of patients in both the pre-
and post-intervention cohorts were classified as having
new TB. A similar majority of patients in both cohorts had
pulmonary tuberculosis, with the remaining patients in
both cohorts having extra-pulmonary tuberculosis. While
52.8% of patients in the pre-intervention cohort hailed
from Clinic A, 65.8% of patients in the post-intervention
cohort were from Clinic B—a statistically significant differ-
ence (Table 1). The proportion of HIV-positive TB patients
not linked to care at baseline as measured by enrolment in
the HIV program at the time of ATT initiation was
Table 1 Baseline Characteristics of Pre- and Post-Intervention
Cohorts
Characteristic Pre-intervention
N = 248
n (%)
Post-intervention
N = 225
n (%)
p-value
Sex
Male 149 (60.1) 119 (52.9) 0.12
Female 99 (39.9) 106 (47.1)
Age, mean (se) 33.7 (0.7) 33.3 (0.7) 0.74
TB Registration Type
New 211 (85.1) 192 (85.3) 0.40
Relapse 35 (14.1) 33 (14.7)
Treatment after
Default or Failure
2 (0.8) 0 (0)
TB Anatomical Site
Pulmonary TB 207 (83.5) 184 (81.8) 0.63
Extra-Pulmonary TB 41 (16.5) 41 (18.2)
Clinic
Clinic A 131 (52.8) 77 (34.2) < 0.01
Clinic B 117 (47.2) 148 (65.8)
Linkage to care Status
Not Linked (Not Enrolled
in HIV Care, not receiving
ART)
159 (64.1) 167 (74.2) 0.02
Linked (Enrolled in HIV
Care, not receiving ART)
89 (35.9) 58 (25.8)
se Standard error, TB Tuberculosis, ART Antiretroviral therapy
Table 2 Linkage to HIV care outcomes for patients not already
in HIV care at baseline (N = 326)
Outcome Pre-intervention Post-intervention p-value
Linked to HIV care within 4 weeks of ATT initiation
All patients 69/159 (43.4%) 90/167 (53.9%) 0.01
Clinic A 40/81 (49.4%) 41/55 (74.6%) < 0.01
Clinic B 29/78 (37.2%) 49/112 (43.8%) 0.37
Linked to HIV care within 8 weeks of ATT initiation
All patients 82/159 (51.6%) 99/167 (59.3%) 0.04
Clinic A 46/81 (56.8%) 45/55 (81.8%) < 0.01
Clinic B 36/78 (46.2%) 54/112 (48.2%) 0.78
Linked to HIV care within 12 weeks of ATT initiation
All patients 87/159 (54.7%) 105/167 (62.9%) 0.03
Clinic A 48/81 (59.3%) 47/55 (85.5%) < 0.01
Clinic B 39/78 (50.0%) 58/112 (51.8%) 0.81
ATT Anti-TB therapy
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74.2%, compared to 64.1% in the pre-intervention cohort
(p = 0.02) (Table 1).
Linkage to HIV care
A total of 147 patients had documented evidence of HIV
program enrolment at the time of ATT initiation, and
thus were excluded from the linkage to care analysis.
Among patients who were not linked at baseline, a
significantly higher proportion of patients in the
post-intervention cohort linked to HIV care by 4, 8, and
12 weeks after ATT initiation, compared to patients in the
pre-intervention cohort at the same time points (Table 2).
By 12 weeks after ATT initiation, 62.9% of patients in the
post-intervention cohort had linked to HIV care, com-
pared to 54.7% in the pre-intervention cohort (p = 0.03).
Stratified by clinic, we observed a significantly higher pro-
portion of patients in the post-intervention cohort at
Clinic A linking to care by 4, 8, and 12 weeks. For Clinic
B, we did not observe a statistically significant difference
in the proportion of patients in the pre- and post-
intervention cohorts linking to HIV care by the time
points of interest (Table 2).
In time-to-event analyses, a significantly higher
proportion of patients in the post-intervention cohortcompared to the pre-intervention cohort linked to care
by 4 weeks (53.9% vs. 43.4%, p = 0.03), but not by 8 weeks
(59.3% vs. 51.6%, p = 0.07) or 12 weeks (62.9% vs. 54.7%,
p = 0.06) (Fig. 2). The median time to HIV care linkage
was 59 days in the pre-intervention cohort versus 25 days
in the post-intervention cohort.
ART initiation
We evaluated ART initiation in both patients who were
linked and not linked to HIV care at baseline (Table 3).
The proportion of all patients at Clinics A and B initiating
ART in the post-intervention cohort by 4 weeks after
ATT initiation was higher in the post-intervention cohort
(29.3%) than the pre-intervention cohort (25.0%), however,
this difference was not statistically significant (p = 0.18)
(Table 3). A significantly higher proportion of patients ini-
tiated ART by 8 weeks in the post-intervention (45.3%)
versus pre-intervention cohort (38.3%) (p = 0.04). Simi-
larly, by 12 weeks after ATT, significantly more
HIV-positive TB patients receiving the intervention had
started ART (52.0%) than those who had not been
exposed to the intervention (41.5%) (p < 0.01). The pro-
portion of patients starting ART within 4, 8, and 12 weeks
of ATT initiation was observed to be consistently higher
in Clinic A than Clinic B for both the pre- and post-inter-
vention cohorts.
In time-to-event analyses, a significantly higher
proportion of patients in the post-intervention versus
pre-intervention cohort had initiated ART early, by
12 weeks (52.0% vs. 41.5%, p = 0.03) after TB treatment
initiation (Fig. 3), but not by 8 weeks (45.3% vs. 38.3%, p =
0.11) or 4 weeks (29.3% vs. 25.0%, p = 0.28). Overall,
median time to ART was 264 days in the pre-intervention
cohort and 78 days in the post-intervention cohort.
Fig. 2 Time to HIV care linkage in the pre- and post-intervention cohorts
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model controlling for age, sex, clinic, TB anatomical site,
and TB registration type, TB patients who received the in-
tegration intervention started ART by 8 weeks post-ATT
at 1.33 times the rate (HR = 1.33, 95% CI: 1.00–1.77) asTable 3 ART initiation outcomes for patients not yet on ART at
the time of TB treatment initiation (N = 473)
Outcome Pre-intervention Post-intervention p-value
Initiating ART within 0 to 4 weeks
All patients 62/248 (25.0%) 66/225 (29.3%) 0.18
Clinic A 40/131 (30.5%) 23/77 (29.9%) 0.92
Clinic B 22/117 (18.8%) 43/148 (29.1%) 0.05
Initiating ART within 0 to 8 weeks
All patients 95/248 (38.3%) 102/225 (45.3%) 0.04
Clinic A 58/131 (44.3%) 41/77 (53.3%) 0.21
Clinic B 37/117 (31.6%) 61/148 (41.2%) 0.11
Initiating ART within 0 to 12 weeks
All patients 103/248 (41.5%) 117/225 (52.0%) < 0.01
Clinic A 61/131 (46.6%) 51/77 (66.2%) < 0.01
Clinic B 42/117 (35.9%) 66/148 (44.6%) 0.15
ART Antiretroviral therapypatients who were not exposed to the intervention, and
this observation was statistically significant (Table 4).
TB treatment outcomes
Among the 473 total patients with HIV-associated TB in
the pre- and post-intervention cohorts, 284 (60.0%) had
a documented TB treatment outcome. Of these, a higher
proportion had a successful outcome (i.e. either micro-
biological cure or documented treatment completion) in
the post-intervention cohort (83.3%) compared to the
pre-intervention cohort (73.9%), although the difference
was of borderline statistical significance (p = 0.051) and
the effect was less pronounced in Clinic B than Clinic A
(Table 5).
In adjusted multivariable logistic regression modelling,
patients receiving the TB/HIV integration intervention
were 2.02 times (95% CI: 1.11–3.67) as likely to have a
successful TB treatment outcome (i.e. achieving cure or
completing treatment) as patients not receiving the
intervention (Table 6).
Discussion
We demonstrate that implementing a one-stop shop
model of TB/HIV service integration significantly
Fig. 3 Time to ART in the pre- and post-intervention cohorts (censored at 12 weeks)
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initiation among patients with HIV-associated TB.
Providing this integrated model in TB clinics does not
detract from TB services, but rather appears to increase
the odds of TB cure or treatment completion. Taken to-
gether, our findings suggest the feasibility of integrating
HIV care and treatment within routine TB clinical
settings in Lusaka, Zambia.
Despite increasing access and coverage of ART in
Zambia [25], there is an on-going need to implement
and evaluate integrated TB/HIV service delivery models
to ensure universal access to ART for patients with
HIV-associated TB. Challenges with linkage to HIV care
and ART initiation for HIV-positive TB patients persist
despite clear national guidelines calling for prompt ART
initiation and compelling clinical trial data documenting
the clear benefits of early ART [13, 26–28]. Reasons for
sub-optimal linkage to HIV care and ART uptake among
patients with HIV-associated TB are thought to be
multifactorial, and include: increased patient transport
and opportunity costs related to the multiple visits gen-
erated by referral-based services; fear among patients
and clinicians about the co-management of side effects
and toxicities; the greater pill burden resulting fromco-treatment; and stigma associated with establishing
HIV care and initiating ART [6, 9, 11, 29–31].
WHO guidelines strongly recommend that ART be
started within 8 weeks of ATT initiation [24]. Zambian
national TB and HIV guidelines reinforce this guidance,
calling for early ART initiation as soon as ATT is toler-
ated, ideally within 2 to 3 weeks of commencing TB
treatment [20]. Yet, no published reports from Zambia
describe the extent to which ART is started early, or the
average time to ART initiation from ATT initiation, for
patients with HIV-associated TB in routine care settings.
In our post-intervention cohort, we observed an average
time to ART from ATT initiation of 78 days, a marked
reduction from the 264 days observed in the pre-
intervention cohort. Similarly, patients who received our
intervention had an increased rate of early ART initi-
ation (by 8 weeks), although ART uptake remained
below 50%. While these findings suggest our interven-
tion improved access to early ART, the relatively low
absolute proportion of patients who received ART by
8 weeks argues for greater investments in HIV services
and health system strengthening to improve integrated
TB/HIV care for patients with HIV-associated TB. In
our Lusaka study clinics, we postulate that the relatively
Table 4 Estimated effect of the integrated TB/HIV treatment
and care intervention, and other covariates, on ART initiation by
8 weeks (N = 473)
Characteristic Unadjusted p-value Adjusteda p-value
HR 95% CI HR 95% CI
Integration Intervention
After 1.25 (0.95, 1.66) 0.12 1.33 (1.00, 1.77) 0.05
Before 1.00
Sex
Female 0.82 (0.62, 1.09) 0.18 0.84 (0.63, 1.12) 0.23
Male 1.00
Age
≥ 35 years 1.21 (0.91, 1.60) 0.19 1.17 (0.89, 1.56) 0.26
< 35 years 1.00
Clinic
Clinic B 0.73 (0.55, 0.97) 0.03 0.71 (0.53, 0.94) 0.02
Clinic A 1.00
TB Site
Extra-pulmonary 0.79 (0.53, 1.17) 0.24 0.81 (0.55, 1.20) 0.29
Pulmonary 1.00
TB Registration Typeb
Treatment after
Default, Failure,
OR Relapse
0.89 (0.60, 1.33) 0.57 0.84 (0.56, 1.26) 0.40
New 1.00
HR Hazard ratio, TB Tuberculosis
aHR estimated by Cox proportional hazard modelling, adjusting for remaining
variables presented in the table
bRelapse, treatment after default, and failure were collapsed into one category
due to collinearity in the model
Table 6 Estimated effect of the integrated TB/HIV treatment
and care intervention, and other covariates, on successful TB
treatment (cure or completion) (N = 284)
Characteristic Unadjusted p-value Adjusteda p-value
OR 95% CI OR 95% CI
Integration Intervention
After 1.77 (0.99, 3.15) 0.05 2.02 (1.11, 3.67) 0.02
Before 1.00
Sex
Female 1.10 (0.61, 1.98) 0.75 1.16 (0.64, 2.13) 0.62
Male 1.00
Age
≥ 35 years 1.05 (0.59, 1.87) 0.87 1.08 (0.60, 1.95) 0.81
< 35 years 1.00
Clinic
Clinic B 0.57 (0.32, 1.02) 0.06 0.50 (0.27, 0.92) 0.03
Clinic A 1.00
TB Site
Extra-pulmonary 0.77 (0.35, 1.69) 0.52 0.82 (0.37, 1.82) 0.62
Pulmonary 1.00
TB Registration Typeb
Treatment after
Default, Failure
OR Relapse
0.94 (0.42, 2.10) 0.89 0.99 (0.43, 2.28) 0.98
New 1.00
ART started within 8 weeks of TB treatment
Yes 1.30 (0.72, 2.32) 0.38 1.16 (0.63, 2.13) 0.63
No 1.00
OR Odds ratio
aOR estimated by logistic regression modelling, adjusting for remaining
variables presented in the table
bRelapse, treatment after default, and failure were collapsed into one category
due to collinearity in the model
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persistent gaps in human resources for health, clinical
infrastructure in TB practice settings, and other service
delivery barriers.
Our intervention featured a one-stop shop model
characterized by complete integration of HIV treatment
and care within existing TB clinics. Using this model,
HIV-infected TB patients received PITC, CPT, ART and
TB services in one clinic space under the care of the
same providers who managed both TB and HIV at the
same visit. Opt-out PITC may have been particularly
important for linking co-infected patients to HIV care asTable 5 Proportion of patients who either were cured or
completed TB treatment during the pre- and post-intervention
periods (N = 284)
Population Pre-intervention
N = 134 n (%)
Post-intervention
N = 151 n (%)
p-value
All patients 99/134 (73.9%) 125/150 (83.3%) 0.05
Clinic A 60/77 (77.9%) 53/58 (91.4%) 0.04
Clinic B 39/57 (68.4%) 72/92 (78.3%) 0.18it has been shown previously to result in higher testing
uptake than traditional opt-in approaches across a var-
iety of settings [32, 33]. In addition, offering on-site HIV
care enrolment and co-localized treatment in the TB
clinics minimized patient referral within and between
facilities, which we postulate helped reduce the kind of
pre-ART loss to follow-up associated with more trad-
itional service integration models [6, 11, 34]. Despite the
availability of these services, however, we observed only
modest linkage to HIV care by 12 weeks post-ATT initi-
ation, which suggests the influence of other patient-,
health system-, and structural-level factors that likely
went unaddressed by our intervention.
Although single-facility integration models have been de-
scribed previously, few reports characterize one-stop shop
approaches to integrate ART provision and HIV care within
TB clinics, and even fewer compare the effects of such ap-
proaches using data from historical or experimental
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ment and care into a rural TB clinic resulted in an increase
in ART initiation (by the end of ATT), from 13% to be-
tween 29 and 36% [37]. In South Africa, integrated TB/HIV
care was associated with significantly fewer unfavourable
ART outcomes, which included death, default, and stopped
treatment, than a vertical care approach [38].
We observed that integrated TB/HIV treatment and care
was associated with increased odds of successful TB treat-
ment. However, only 83.3% of patients achieved cure or
completed treatment in the post-intervention period. While
this proportion compares favourably with national figures
reported to WHO for the study period, and TB outcomes
for other integrated approaches documented in the region
[38], it nonetheless falls below the Global Plan to End TB
target of at least 90% of patients experiencing treatment
success [19, 39]. Of note, TB treatment success at Clinic A
exceeded 90%, but failed to surpass 80% in Clinic B, sug-
gesting differences in the implementation context and bar-
riers to introducing our intervention between TB clinics.
In both TB clinics, we encountered several noteworthy
barriers to introducing integrated treatment and care.
Limited clinic capacity and human resources, in particular,
presented barriers to integrated service delivery, as reported
elsewhere [11, 40]. At one study clinic, we encountered hu-
man resource challenges of frequent staff shortages, sched-
uling issues, and turnover, and addressed these directly
through training, re-training, and mentorship. While it is
possible that we could have strengthened our model by
placing long-term project staff in the TB clinics, given our
resource limitations we opted for a more sustainable
approach focused on building the capacity of existing
MOH staff to deliver integrated services. Similar to other
settings, clinicians reported concerns over managing co-
infected patients and co-administering ART and ATT,
fearing the development of adverse events, such as immune
reconstitution inflammatory syndrome [41, 42]. Some staff
were not motivated to support integrated activities, espe-
cially if the activities were perceived as extra work. Indeed,
overburdened staff has been cited as an important barrier
to implementing integrated TB/HIV activities [43]. Anec-
dotally, we perceived this to be a clinic-specific issue: in
Clinic B, reluctance among some staff to adopt the inter-
vention may have contributed to poorer ART initiation out-
comes; while in Clinic A, staff more uniformly welcomed
TB/HIV integration and acknowledged it as a more effi-
cient way to provide care. Results from other pilot projects
suggest that TB/HIV integration may be a means to im-
prove health worker knowledge, motivation, and retention
[3]. Lastly, issues with supply chain management in the TB
clinic resulted in intermittent sputum container and TB
diagnostic reagent stock outs. In Malawi, similar supply
chain challenges affected uptake of integrated HIV services
among co-infected patients [9].In responding to these challenges, several “key lessons
learned” emerged. First, involving policy makers, facility
in-charges, health workers, and other leadership in
program planning from the outset was essential for
obtaining local buy-in, and highlight the importance of
obtaining visible MOH support and sensitizing staff
pre-implementation to achieve adequate integration.
Second, weekly clinic team meetings provided a forum
to discuss challenges and identify and disseminate
clinic-level best practices. Third, site-based mentoring
enabled clinical officers to develop practical clinical skills
and confidence in TB/HIV co-management. Fourth, longi-
tudinal technical support for organizational and logistical
problem solving led to improvements in patient flow and
supply chain management for TB and HIV commodities.
Fifth, adequate clinical space was essential for ensuring
ART integration [40]. We found that clinics with at least 3
rooms worked best: one room allowed new patient enrol-
ments and daily medication dispensing; a second room
enabled patient examination on ART/TB clinic days; and
a third room facilitated health commodity storage and pri-
vate counselling space for HCT. Sixth, we found that
integrated care functioned best when a dedicated,
ART-trained clinical officer was assigned to staff the TB
clinic. In Zambia, this clinical officer provided necessary
clinical support to two nurses overseeing TB clinic opera-
tions. These nurses functioned daily to enrol into HIV care
any TB patient newly diagnosed with HIV and to schedule
appointments for clinician review and ART initiation.
From the client perspective, several patients anecdotally
expressed a preference for our integrated care model.
Similar patient preference has been reported previously
in South Africa, especially for patients from lower so-
cioeconomic strata [44]. Patients expressed an appreci-
ation for the shorter waiting times and reduced stigma in
the integrated TB clinic compared to the ART clinic, as
well as the added convenience of our one-stop shop ap-
proach. In some cases, patients were reluctant to return to
their general ART clinic after completion of TB treatment
[11]. Qualitative research is required to further examine
patient preferences regarding, and the patient-specific
challenges surrounding, integrated TB/HIV care [31].
While the absence of qualitative data limited our abil-
ity to formally explore patient preferences regarding in-
tegrating HIV treatment and care into TB clinics, such
an analysis was beyond the scope of this study. Our
study was also limited by missing TB treatment outcome
data for approximately 40% of the patients in our study.
Missing data resulted from the inability to ascertain
paper-based TB treatment outcomes for patients who did
not return for a final TB clinic visit and could not be
traced, and those who transferred out from our study sites
during the course of their anti-TB therapy. These issues,
along with our study having been conducted in only two
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findings. Our study was also not designed to ascertain re-
tention in HIV care, including retention after patient com-
pletion of ATT when they were referred to the ART clinic
for continued HIV management. Similarly, we did not as-
sess the effects of other important clinical, behavioural,
and structural factors on linkage to care and ART uptake
for patients with HIV-associated TB, including baseline
CD4 count, perceived HIV- and TB-related stigma,
co-morbid mental illness and substance use, and distance
from patients’ homes to the health facility. Lastly, the use
of existing, de-identified program data precluded our abil-
ity to corroborate observational findings from elsewhere
in SSA suggesting that integrated TB/HIV care reduces
mortality among co-infected patients [45, 46].
Conclusions
We demonstrate that it is feasible to integrate HIV treat-
ment and care, including ART, within public TB clinics in
urban Zambia, while concurrently improving TB treatment
outcomes. We describe an integrated model of TB/HIV
treatment and care characterized by: the same health
workers providing both TB and HIV services with the help
of longitudinal training and mentorship; dedicated staffing,
space, and clinic days for delivering all integrated services
in the same clinic; and synchronized TB and HIV follow-up
to ensure one-stop shopping for patients seeking care at a
single TB clinic. Using this model, we achieved increases in
linkage to care and early ART uptake for patients with
HIV-associated TB. Additional studies are needed to iden-
tify new strategies to further improve integrated care and
ART uptake, retention, and viral suppression among
patients with HIV-associated TB in Zambia, in line with
national and international targets. Further research is also
needed to elucidate the patient-, health system-, and
structural-level factors that enable or impede integrated
care and the impact these factors have on joint, longitudinal
TB/HIV clinical outcomes. Finally, additional investments
are needed to ensure adequate human resources for health
and health systems sufficiently robust to deliver high-
quality, integrated services along the entire TB/HIV care
continuum for patients with HIV-associated TB in SSA.
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